Michael King
Stock Analyst at EF Hutton
(0.79)
# 3,984
Out of 5,033 analysts
116
Total ratings
34.43%
Success rate
-15.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
APLM Apollomics | Maintains: Buy | $1,100 → $650 | $30.10 | +2,059.47% | 4 | Apr 1, 2024 | |
SONN Sonnet BioTherapeutics Holdings | Assumes: Buy | $1,179 | $4.01 | +29,306.48% | 7 | Aug 23, 2023 | |
LTRN Lantern Pharma | Reiterates: Buy | $11 | $4.12 | +167.31% | 10 | Aug 10, 2023 | |
BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.60 | +1,900.00% | 11 | Jun 26, 2023 | |
JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $2.51 | +2,629.08% | 10 | Jun 12, 2023 | |
COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $14.98 | +1,235.11% | 7 | May 25, 2023 | |
HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $1.62 | +412.35% | 6 | May 25, 2023 | |
REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $576.77 | +49.45% | 11 | May 1, 2023 | |
EXEL Exelixis | Reiterates: Buy | $24 | $34.54 | -30.52% | 10 | Apr 28, 2023 | |
AGEN Agenus | Reiterates: Buy | $166 | $4.42 | +3,655.66% | 8 | Mar 28, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $15.07 | +178.70% | 5 | Feb 24, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $491.22 | -38.11% | 2 | Feb 24, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $27.98 | +314.58% | 6 | Feb 24, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.05 | +154.32% | 2 | Dec 16, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $27.92 | -14.04% | 1 | Mar 23, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15,000 → $12,000 | $4.05 | +296,196.30% | 2 | Mar 11, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $35.27 | +30.42% | 3 | Mar 8, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $42.65 | +125.09% | 6 | Mar 3, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.75 | +4,676.44% | 1 | Jan 10, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $16.22 | +91.12% | 2 | Nov 5, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $849.46 | -95.76% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $30.10
Upside: +2,059.47%
Sonnet BioTherapeutics Holdings
Aug 23, 2023
Assumes: Buy
Price Target: $1,179
Current: $4.01
Upside: +29,306.48%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $4.12
Upside: +167.31%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.60
Upside: +1,900.00%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $2.51
Upside: +2,629.08%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $14.98
Upside: +1,235.11%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $1.62
Upside: +412.35%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $576.77
Upside: +49.45%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $34.54
Upside: -30.52%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $4.42
Upside: +3,655.66%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $15.07
Upside: +178.70%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $491.22
Upside: -38.11%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $27.98
Upside: +314.58%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $4.05
Upside: +154.32%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $27.92
Upside: -14.04%
Mar 11, 2022
Maintains: Buy
Price Target: $15,000 → $12,000
Current: $4.05
Upside: +296,196.30%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $35.27
Upside: +30.42%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $42.65
Upside: +125.09%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.75
Upside: +4,676.44%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $16.22
Upside: +91.12%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $849.46
Upside: -95.76%